Our comprehensive analysis demonstrated increased levels of a broad range of biomediators (54 out of 80) in severely to critically ill patients with COVID-19 and the expression profile of cytokines and chemokines in COVID-19 was also much broader than that in RA or iMCD, for which IL-6 blockade therapy has been already approved, suggesting activation of a wide spectrum of inflammatory cells. Here, IL6 is linked to COVID-19.